Beta blockers Osteoporosis , Osteopenia
Beta blockers Osteoporosis, Osteopenia and better bone density November 2010 saw another publication documenting the positive effect of these drugs on bone density. This is not the first time that researchers have found this somewhat surprising connection. But those with coronary disease who have been prescribed this medication will be glad to know of thesepositive results.
- Association between beta-blocker use and fracture risk: The Dubbo Osteoporosis Epidemiology Study. BY Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. published in Bone 2010 Nov 1.
Among 3,488 participants, 262 (20%) men and 411 (19%) women received β-blockers (BB). In men, BB use was associated with higher BMD at the femoral neck (0.96 versus 0.92 g/cm2, P < 0.01), higher lumbar spine BMD (1.32 vs. 1.25 g/cm2, P < 0.01), and lower fracture risk (odds ratio = 0.49, 95% CI: 0.32-0.75) than those not on BB.
In women, BB users also had higher femoral neck BMD (0.83 vs. 0.81g/cm2, P < 0.01), higher lumbar spine BMD (1.11 vs. 1.06 g/cm2, P < 0.01), and lower risk of fracture (odds ratio = 0.68, 95% CI: 0.53-0.87) than non-users. This risk reduction is large. Whether there are confounders present remains to be determined. —ES
- 2004 Beta blockers Osteoporosis, Osteopenia, bone mineral density study. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. Submitted by Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC; Geelong Osteoporosis Study. Bone Miner Res. 2004 Jan;19(1):19-24.
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia. firstname.lastname@example.org
This population-based study documented beta-blocker use in 59/569 cases with incident fracture and 112/775 controls. OR for fracture associated with beta-blocker use was 0.68 (95%CI, 0.49-0.96). Beta-blockers were associated with higher BMD at the total hip (2.5%) and UD forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. Beta-blocker use is associated with reduced fracture risk and higher BMD.
INTRODUCTION: Animal data suggests that bone formation is under beta-adrenergic control and that beta-blockers stimulate bone formation and/or inhibit bone resorption.
MATERIALS AND METHODS: We evaluated the association between beta-blocker use, bone mineral density (BMD), and fracture risk in a population-based study in Geelong, a southeastern Australian city with a single teaching hospital and two radiological centers providing complete fracture ascertainment for the region. Beta-blocker use was documented for 569 women with radiologically confirmed incident fractures and 775 controls without incident fracture. Medication use and lifestyle factors were documented by questionnaire.
RESULTS: Odds ratio for fracture associated with beta-blocker use was 0.68 (95% CI, 0.49-0.96) for any fracture. Adjusting for age, weight, medications, and lifestyle factors had little effect on the odds ratio. Beta-blocker use was associated with a higher BMD at the total hip (2.5%, p = 0.03) and ultradistal forearm (3.6%, p = 0.04) after adjustment for age, anthropometry, and thiazide use.
CONCLUSION: Beta-blockers are associated with a reduction in fracture risk and higher BMD.
- For an even earlier study on this topic click on: Beta blockers Osteoporosis, Osteopenia and bone density
Go to: Medical treatments page